Immunitybio Inc IBRX

$10.28 +1.01 (10.83%)

Valuation

Market cap
9,835,278,000
Revenue TTM
$113,290,000
Net income TTM
$-351,400,000
PE ratio
0.00
Forward PE
—
Profit margin
-310.18%
Debt to equity
0.00

Trading

Volume
31,251,500
Avg volume
10,344,540
Day's range
$9.39 – $10.55
Shares out
1,059,836,000
Stochastic %K
88%
Beta
0.02
Analysts
Strong Sell
Price target
$12.20

Price

Company profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The com...

Show more

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
844 696 5235
Website
https://immunitybio.com
Address
3530 John Hopkins Court, San Diego, United States

Latest news

Stocktwits

DotKnight Oct 4, 12:07 AM
$IBRX Roger Stone interviewed Dr. PATRICK a while ago and mentioned Dr. Cured his friend. Roger is a good friend of Michael. Roger's wife had cancer too and cancer free more than 5 years.
1 replies
arnolddiver Oct 4, 12:01 AM
$IBRX IBRX’s NK CELL pipeline’s main competition is IN VIVO CAR-T. Big Pharma is investing heavily in in vivo bc ex vivo car-t is too expensive and the turnaround time is long. Tinkering with cells outside the body then injecting back into the body is costly. The issue with in vivo car-t though is toxicity. Dr Pat is fixing the cost and turnaround time issue with AI used in the Leonardo. The machine works 24/7 with no human touch. Amazing efficiency! Dr Pat said it will cut costs by 1/10 of current Car-T. We already know nk cells are allogeniec and most important, safe. There are no tox issues. Coupled with Anktiva, durability should be stellar. My bet is on NK Cells. Big Pharma prob now saying oh crap these tox issues are worse than we thought.
0 replies
MrMulally Oct 3, 11:58 PM
$IBRX Another great post PureLand. You mentioned 👇 this company could become the NVDA of biotech. Here’s an excerpt from our good Dr. Pat’s response to an analyst during Q4 earning call. The possibility is endless at global scale with Anktiva and thats what our good Dr. is doing. “Global expansion unstoppable!!” “Our cancer moonshot coming to fruition”
0 replies
Biofrog Oct 3, 11:50 PM
$IBRX I love the weekends. Conversation not so fast and people can develope better conversations. Great weekend so far. I have to say that in 4 years this pps will be well over $300.
1 replies
Lookin4retirement Oct 3, 11:47 PM
$IBRX The rising price is nice but I’m in this for a cancer cure and I truly believe Anktiva will be a pillar of the cure. I would love to hear that St Jude kids are being cured since they are using Anktiva. For those that believe please say a prayer for the kids that are diagnosed with cancer and everyone with that has that terrible disease. May God heal them and give wisdom to the FDA to take the chains off Anktiva and allow Gods cancer fighting molecules do what he designed them to do.
0 replies
arnolddiver Oct 3, 11:34 PM
$IBRX related to share count and capital needs, there are still around 41m warrants on the books as of June end. Not sure why they havent been exercised but when they do, IBRX will get around $120M added to its balance sheet but increased share count dilution. Hopefully, the warrant holders exercise b4 Dr Pat even considers raising cash. These warrants are very profitable now.
1 replies
Skipper6 Oct 3, 11:29 PM
$IBRX ...@John_morrris, we having fun yet?? Skipper
1 replies
arnolddiver Oct 3, 11:28 PM
$IBRX this is HUGE. I had no idea Trump’s Cancer Panel even existed. Caputo is one of Trump’s best friends and close confidantes. Caputo is cancer free but says his body has been wrecked with chemo and radiation. He is now focusing on recovery. Wow sounds like what he needs is ANKTIVA and NK CELLS to boost his immune system to feel normal again. Also, Caputo lives in Florida. Close to the big time GOP donors, Dr K and his wife, who made the http://lymphocytecount.org website. The wife credits Anktiva saving her life.
0 replies